---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-013033"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:53:12.440689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lineage Q1 net loss $7.1M ($0.04/sh); cash $78.1M; pipeline expanded

## Summary
- Net loss attributable to Lineage of $7.1M ($0.04/sh) vs $1.4M ($0.01/sh) in Q1 2021.
- Total revenues $5.2M, up from $0.4M YoY, driven by $50M Roche upfront licensing fee.
- Cash and cash equivalents $78.1M as of March 31, 2022.
- Pipeline expanded with two new cell therapy programs: auditory neurons (ANP1) and photoreceptors (PNC1).
- VAC2 Phase 1 NSCLC enrollment completed; IND submission for US testing expected 2H 2022.

## SEC filing metadata
- accession: 0001493152-22-013033
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222013033/0001493152-22-013033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222013033/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-013033
- JSON: https://secwatch.observer/filing/0001493152-22-013033.json
- Plain text: https://secwatch.observer/filing/0001493152-22-013033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.